Wednesday, June 10, 2026
🇺🇸 FDA

pharma · Critical Limb Ischemia (CLI) · Sarcoma · DSGN

Lxo Ireland Designated

Lxo Ireland Designated Activity Company

Lxo Ireland Designated clinical programs — 68 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.

CARLSBAD, CA, IE HQ
Public company Type
DSGN · NYSE Ticker
Company details
Status
Public
HQ
CARLSBAD, CA, IE
Programs
68
Drugs
61
Patents
201
All projects Drug pipeline Patents News & analysis

Recent coverage

View all news & analysis →
Intelligence · Clinical Programs

Lxo Ireland Designated projects

68 ClinicalTrials.gov programs sponsored by Lxo Ireland Designated.

Lxo Ireland Designated has 68 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.

All phases Phase III Phase II Phase I NDA / BLA filed Approved programs

68 programs

Clinical programs

Page 1 of 2

  1. ANDA219975 + ANDA220011

    Lxo Ireland Designated Activity Company

    Type 2 Diabetes

    phase 3 small molecule active

    1 trial

  2. Abiraterone - Usual

    Lxo Ireland Designated Activity Company

    Prostate Cancer

    phase 3 small molecule active

    1 trial

  3. Alectinib - Usual

    Lxo Ireland Designated Activity Company

    ALK-Positive Non-Small Cell Lung Cancer (NSCLC)

    phase 3 small molecule active

    1 trial

  4. Amchafibrin

    Lxo Ireland Designated Activity Company

    Osteoarthritis, Knee

    phase 3 small molecule completed

    1 trial

  5. Cloxacilin

    Lxo Ireland Designated Activity Company

    Staphylococcus

    phase 3 small molecule terminated

    1 trial

  6. Conventional medical treatment

    Lxo Ireland Designated Activity Company

    Coronary Atherosclerosis and Other Heart Disease

    phase 3 small molecule completed

    1 trial

  7. Discontinuation antipsychotic treatment

    Lxo Ireland Designated Activity Company

    Psychosis Nos/Other

    phase 3 small molecule active

    1 trial

  8. ETOPOSIDE - Usual

    Lxo Ireland Designated Activity Company

    Small Cell Lung Cancer

    phase 3 small molecule active

    1 trial

  9. Influenza vaccine

    Lxo Ireland Designated Activity Company

    Infection in Solid Organ Transplant Recipients

    phase 3 mab completed

    1 trial

  10. LV305

    Lxo Ireland Designated Activity Company

    Synovial Sarcoma

    phase 3 mab terminated

    1 trial

  11. Levodopa

    Lxo Ireland Designated Activity Company

    Ischaemic Stroke

    phase 3 small molecule completed

    1 trial

  12. Paclitaxel-releasing PTA balloon catheter

    Lxo Ireland Designated Activity Company

    Arteriovenous Fistula Renal Dialysis Devices Obstruction

    phase 3 other completed

    1 trial

  13. Platelet rich plasma

    Lxo Ireland Designated Activity Company

    Coxarthrosis

    phase 3 small molecule completed

    1 trial

  14. REX-001

    Lxo Ireland Designated Activity Company

    Peripheral Arterial Disease (PAD)

    phase 3 small molecule terminated

    2 trials

  15. Raloxifene - Usual

    Lxo Ireland Designated Activity Company

    Breast Cancer

    phase 3 small molecule active

    1 trial

  16. Rituximab

    Lxo Ireland Designated Activity Company

    Lupus Nephritis

    phase 3 mab terminated

    1 trial

  17. Topotecan - usual

    Lxo Ireland Designated Activity Company

    SCLC

    phase 3 small molecule active

    1 trial

  18. ALLOGENEIC AND EXPANDED ADIPOSE TISSUE-DERIVED MESENCHYMAL STEM CELLS

    Lxo Ireland Designated Activity Company

    Sars-CoV2

    phase 2 small molecule completed

    1 trial

  19. Adult Allogeneic Mesenchymal cells from adipose tissue.

    Lxo Ireland Designated Activity Company

    Acute Graft Versus Host Disease

    phase 2 small molecule completed

    1 trial

  20. Anterior lamellar nanostructured artificial human cornea.

    Lxo Ireland Designated Activity Company

    Severe Trophic Corneal Ulcers Refractory to Conventional Treatment

    phase 2 small molecule completed

    1 trial

  21. Autologous Bone Marrow Mononuclear Cells

    Lxo Ireland Designated Activity Company

    Peripheral Vascular Diseases

    phase 2 other completed

    1 trial

  22. Autologous adipose derived mesenchymal stem cells

    Lxo Ireland Designated Activity Company

    Critical Limb Ischemia (CLI)

    phase 2 small molecule completed

    1 trial

  23. Autologous mesenchymal stem cells from adipose tissue.

    Lxo Ireland Designated Activity Company

    Autoimmune Diseases

    phase 2 other completed

    1 trial

  24. Bioengineered Artificial Mesenchimal Sheet (BAMS)

    Lxo Ireland Designated Activity Company

    Venous Ulcer

    phase 2 mab active

    1 trial

  25. Bone marrow mesenchymal stem cells autologous

    Lxo Ireland Designated Activity Company

    Multiple Sclerosis

    phase 2 other completed

    1 trial

  26. Bone marrow mononuclear cells

    Lxo Ireland Designated Activity Company

    Chronic Myocardial Ischemia

    phase 2 other completed

    1 trial

  27. CMB305

    Lxo Ireland Designated Activity Company

    Sarcoma

    phase 2 mab terminated

    2 trials

  28. CMMo/RH/2009

    Lxo Ireland Designated Activity Company

    Liver Transplant Rejection

    phase 2 other completed

    1 trial

  29. Combination of MK3475 with Metronomic CP

    Lxo Ireland Designated Activity Company

    Sarcoma

    phase 2 small molecule completed

    1 trial

  30. DT-168

    Lxo Ireland Designated Activity Company

    Fuchs Endothelial Corneal Dystrophy

    phase 2 small molecule active

    1 trial

  31. DT-216P2

    Lxo Ireland Designated Activity Company

    Friedreich Ataxia

    phase 2 small molecule active

    2 trials

  32. EudraCT: 2008-004014-27

    Lxo Ireland Designated Activity Company

    Graft Versus Host Disease

    phase 2 other completed

    1 trial

  33. FIB-BIO-2023-03

    Lxo Ireland Designated Activity Company

    Cleft Lip and Palate

    phase 2 other active

    1 trial

  34. G100

    Lxo Ireland Designated Activity Company

    Follicular Low Grade Non-Hodgkin's Lymphoma

    phase 2 small molecule terminated

    1 trial

  35. Gabapentin

    Lxo Ireland Designated Activity Company

    Sickle Cell Disease

    phase 2 small molecule completed

    1 trial

  36. Hyperimmune plasma

    Lxo Ireland Designated Activity Company

    SARS-CoV 2

    phase 2 mab completed

    1 trial

  37. IMD-1041

    Lxo Ireland Designated Activity Company

    Chronic Obstructive Pulmonary Disease

    phase 2 small molecule active

    1 trial

  38. Infusion of MSC

    Lxo Ireland Designated Activity Company

    Discordant Immunological Response in HIV Infected Subjects

    phase 2 small molecule completed

    1 trial

  39. Infusion of autologous mononuclear bone marrow cells

    Lxo Ireland Designated Activity Company

    Idiopathic Dilated Cardiomyopathy

    phase 2 small molecule terminated

    1 trial

  40. Infusion of mesenchymal stem cells from adipose tissue

    Lxo Ireland Designated Activity Company

    Faecal Incontinence

    phase 2 small molecule completed

    1 trial

  41. Injectable suspension of allogeneic adult mesenchymal stem cells

    Lxo Ireland Designated Activity Company

    Hidradenitis Suppurativa

    phase 2 mab active

    1 trial

  42. Intraarterial infusion of autologous bone marrow cells

    Lxo Ireland Designated Activity Company

    Critical Limb Ischemia (CLI)

    phase 2 other completed

    2 trials

  43. Intracoronary infusion of autologous bone marrow cells

    Lxo Ireland Designated Activity Company

    Dilated Cardiomyopathy

    phase 2 other completed

    1 trial

  44. Intravenous administration of 1 million of MSC

    Lxo Ireland Designated Activity Company

    Amyotrophic Lateral Sclerosis

    phase 2 small molecule completed

    1 trial

  45. Mesenchymal stem cells from adipose tissue

    Lxo Ireland Designated Activity Company

    Critical Limb Ischemia

    phase 2 other completed

    1 trial

  46. PHITAH

    Lxo Ireland Designated Activity Company

    Basal Cell Carcinoma

    phase 2 mab active

    1 trial

  47. Stem cell infusion

    Lxo Ireland Designated Activity Company

    Critical Limb Ischemia (CLI)

    phase 2 small molecule terminated

    1 trial

  48. 9vHPV Vaccine plus BCG Vaccine Mix for percutaneous use

    Lxo Ireland Designated Activity Company

    HPV Infection

    phase 1 mab active

    1 trial

Frequently asked questions

How many clinical projects does Lxo Ireland Designated have?

68 published programs are linked to this sponsor in our ClinicalTrials.gov index.

Is this the complete company pipeline?

This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.